Table 3 Multivariable analysis in ovarian cancer patients
From: BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
Variable | Progression-free survival | Overall survival | |||
|---|---|---|---|---|---|
HR of progression (95% CI) | P value | HR of death (95% CI) | P value | ||
A | |||||
Age | Low vs. high (<or>median age) | – | – | 1.9 (1.3–2.9) | 0.001 |
FIGO stage | I/II vs. III/IV | 2.6 (1.2–5.5) | 0.013 | 1.1 (0.6–2.1) | 0.692 |
Residual disease after surgery | No vs. yes | 2.7 (1.6–4.6) | <0.001 | 3.5 (2.1–6.0) | <0.001 |
Histology | HGSOC vs. Others | 0.9 (0.6–1.5) | 0.675 | 0.6 (0.4–1.1) | 0.087 |
Ovarian cancer type | Type I vs. Type II | – | – | 0.9 (0.3–2.7) | 0.829 |
BRCA1 mRNA expression | Low vs. high (<or>optimal cut-off) | – | – | 2.0 (1.1–3.7) | 0.028 |
BRCA2 mRNA expression | Low vs. high (<or>optimal cut-off) | 1.9 (1.0–3.7) | 0.061 | 1.9 (1.0–3.7) | 0.058 |
B | |||||
Age | Low vs. high (<or>median age) | – | – | 2.1 (1.3–3.4) | 0.002 |
FIGO stage | I/II vs. III/IV | 2.3 (0.8–6.3) | 0.119 | 1.1 (0.5–2.4) | 0.812 |
Residual disease after surgery | No vs. yes | 2.4 (1.3–4.7) | 0.008 | 3.2 (1.7–6.0) | <0.001 |
BRCA1 mRNA expression | Low vs. high (<or>optimal cut-off) | – | – | 1.7 (0.8–3.5) | 0.151 |
BRCA2 mRNA expression | Low vs. high (or>optimal cut-off) | 2.4 (1.0–5.7) | 0.045 | 2.9 (1.2–6.8) | 0.015 |
